You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD123-CD33 cCAR

Showing 26 - 50 of 5,178
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High-risk MDS, Acute Myelogenous Leukemia, Systemic Mastocytosis Trial in Minneapolis, Madison (GTB-3550 TriKE® Phase I,

Terminated
  • High-risk Myelodysplastic Syndromes
  • +3 more
  • GTB-3550 TriKE® Phase I
  • GTB-3550 TriKE® Phase II
  • Minneapolis, Minnesota
  • +1 more
Mar 21, 2022

Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in

Recruiting
  • Recurrent Acute Leukemia
  • +16 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory Trial in Philadelphia

Recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • CART123 cells; cyclophosphamide; fludarabine
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Feb 28, 2022

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Baltimore, Maryland
  • +1 more
Dec 13, 2022

Acute Myeloid Leukemia (AML) Trial in Germany (Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP))

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Cyclophosphamide (Non-IMP)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +5 more
Dec 28, 2021

Leukemia, Myeloid, Acute Trial in Chongqing (anti-CD33 CAR NK cells, Fludarabine, Cytoxan)

Recruiting
  • Leukemia, Myeloid, Acute
  • anti-CD33 CAR NK cells
  • +2 more
  • Chongqing, Chongqing, China
    Department of Hematology, Xinqiao Hospital
Dec 22, 2021

Leukemia, Myeloid, Acute Trial in Canada, United States (VOR33, Mylotarg)

Recruiting
  • Leukemia, Myeloid, Acute
  • La Jolla, California
  • +8 more
Jan 31, 2023

Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Charlottesville (Tagraxofusp)

Recruiting
  • Myelofibrosis
  • +2 more
  • Charlottesville, Virginia
    Danyelle Coley
Jan 18, 2023

Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma Trial in Shenzhen, Chengdu (BCMA-CD19 cCAR T

Recruiting
  • Multiple Myeloma in Relapse
  • +2 more
  • BCMA-CD19 cCAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
May 17, 2021

Acute Myeloid Leukemia Trial in Wuxi (Anti-CD33/CLL1 CAR-NK Cells)

Recruiting
  • Acute Myeloid Leukemia
  • Anti-CD33/CLL1 CAR-NK Cells
  • Wuxi, Jiangsu, China
    Wuxi People's Hospital
Jan 18, 2022

Leukemia, Myeloid, Acute Trial in Baltimore (Flotetuzumab)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aug 16, 2022

Acute Myeloid Leukemia Trial in Beijing (Dual CD33/CLL1 CAR T)

Recruiting
  • Acute Myeloid Leukemia
  • Dual CD33/CLL1 CAR T
  • Beijing, Beijing, China
    Beijing Boren Hospital
Feb 16, 2022

AML, Adult Trial in Tianjin (QN-023a, Cyclophosphamid, Fludarabine)

Recruiting
  • AML, Adult
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 3, 2022

Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte

Active, not recruiting
  • Adult Acute Myeloid Leukemia in Remission
  • +12 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Healthy Adults Trial in Créteil (Solo 0.3 group, Solo 1 group, Solo 3 group)

Recruiting
  • Healthy Adults
  • Solo 0.3 group
  • +5 more
  • Créteil, France
  • +2 more
Sep 9, 2022

Leukemia, Myeloid, Acute Trial in Chongqing (Fludarabine, Cytoxan, Dual CD33-CLL1 CAR-T cells)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • Chongqing, Chongqing, China
    Department of Hematology, Xinqiao Hospital
Aug 20, 2021

Acute Myeloid Leukemia Trial in Italy (tagraxofusp)

Recruiting
  • Acute Myeloid Leukemia
  • Bergamo, Italy
  • +7 more
Dec 17, 2021

Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myeloid Neoplasm
  • Biospecimen Collection
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 5, 2023

Leukemia, Myeloid, Acute Trial in Spain, United States (JNJ-63709178)

Completed
  • Leukemia, Myeloid, Acute
  • Detroit, Michigan
  • +9 more
Aug 30, 2021

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in Kunming (CD123 CAR-T cells)

Recruiting
  • Leukemia
  • +2 more
  • CD123 CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
Mar 1, 2021

Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia Trial

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • +7 more
  • Anti-CD123 ADC IMGN632
  • +7 more
  • (no location specified)
Dec 28, 2022

Blastic Plasmacytoid Dendritic Cell Tumor, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Worldwide (IMGN632)

Recruiting
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • +3 more
  • Gilbert, Arizona
  • +14 more
Apr 20, 2022

Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor Trial in United

Completed
  • Acute Myelogenous Leukemia
  • +3 more
  • XmAb14045
  • Jacksonville, Florida
  • +8 more
Mar 4, 2022